The first startup is usually where a founder learns what they don’t know. The second is where that knowledge starts to pay off.
In artificial intelligence, the pattern is becoming hard to miss. A growing share of the most closely watched AI companies are led by people who have already built, scaled, and sold a business. They arrive with networks, credibility with investors, and, perhaps most valuable, a clearer sense of which problems are worth a decade of their lives.
Lessons From an Early AI Exit
Consider the path of serial founder Daniel Nadler. Long before generative AI became a household term, he co-founded Kensho Technologies in 2013 to apply machine learning to financial analysis.
The company drew attention quickly and was recognized at the 2017 World Economic Forum as one of the most innovative technology companies in the world.
In 2018, S&P Global completed its acquisition of Kensho, a deal reported at $550 million. At the time, it was one of the more notable exits for an AI company, years before the current wave of investment.
Kensho reinforced a lesson that many first-generation AI founders learned the hard way. Models are only as good as the data they are built on and the workflow they fit into. A technically impressive system that does not slot into how professionals actually work tends to stall.
Choosing a Harder Problem
Second-time founders often pick bigger, messier problems, partly because they can. Nadler’s next company, OpenEvidence, took on clinical medicine, where the stakes are higher and the users arguably more skeptical than on Wall Street.
The motivation was personal. According to Forbes, his grandfather had died due to a medical error, an experience Nadler has cited as part of what drew him to the problem of getting better evidence to physicians.
The experience of a first company showed in how the second was built. Rather than training on the open web, OpenEvidence focused on peer-reviewed literature and signed content agreements with major journals. It also made the product free for verified clinicians, letting physicians adopt it on their own before a hospital ever had to approve a budget.
Capital Follows Track Records
Investors tend to move faster for founders who have done it before. OpenEvidence raised a $210 million round in July 2025 at a $3.5 billion valuation, with GV and Kleiner Perkins co-leading.
Just three months later, it raised $200 million at a $6 billion valuation. By January 2026 it was valued at $12 billion, and in September 2026 it raised another $250 million at a $15 billion valuation.
What Other Founders Can Take From It
A few lessons travel well beyond medicine. First, the quality of your inputs sets the ceiling on your product, so invest early in proprietary or licensed data. Second, pick a problem with real urgency, one that users feel every day, because urgency drives adoption more reliably than novelty. Third, design distribution into the product. A tool that professionals can start using without a procurement cycle can grow faster than one that depends on a large sales team.
None of this guarantees a second success. Plenty of serial founders stumble the second time around. But in a field moving as fast as AI, the hard-won judgment of someone who has already shipped, scaled, and sold a company is a meaningful advantage.


